利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

291 records (took 0.027 seconds)

    METHOD RELATING TO MYOSTATIN PATHWAY INHIBITION
    22.
    发明公开
    METHOD RELATING TO MYOSTATIN PATHWAY INHIBITION 审中-公开

    公开(公告)号：US20230273221A1

    公开(公告)日：2023-08-31

    申请号：US18312879

    申请日：2023-05-05

    Applicant: UCL Business Ltd.

    Inventor： Thomas Voit ,  Julie Dumonceaux ,  Virginie Mariot

    IPC: G01N33/68 ,  A61K38/17 ,  G01N33/74

    CPC classification number: G01N33/6887 ,  A61K38/177 ,  G01N33/74 ,  G01N2800/52

    Abstract: The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.

    THERAPEUTIC USE OF COMPOUNDS
    26.
    发明公开
    THERAPEUTIC USE OF COMPOUNDS 审中-公开

    公开(公告)号：US20230146709A1

    公开(公告)日：2023-05-11

    申请号：US17903372

    申请日：2022-09-06

    Applicant: UCL BUSINESS LTD

    Inventor： Robin Simon Brooke Williams ,  Matthew Walker

    IPC: A61K31/20

    CPC classification number: A61K31/20

    Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the γ carbon of R1, or of only single methyl groups at both the β and ω-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.

    END-EFFECTOR FOR ENDOSCOPIC SURGICAL INSTRUMENT
    28.
    发明申请
    END-EFFECTOR FOR ENDOSCOPIC SURGICAL INSTRUMENT 有权

    公开(公告)号：US20230068155A1

    公开(公告)日：2023-03-02

    申请号：US17819757

    申请日：2022-08-15

    Applicant: UCL Business LTD.

    Inventor： Danail STOYANOV ,  Hani Joseph MARCUS ,  Emmanouil DIMITRAKAKIS

    IPC: A61B17/00

    Abstract: An end-effector for an endoscopic surgical instrument, the end-effector comprising: a tool configured to interact with tissue; a main body comprising a bearing stud, the tool being connected to the bearing stud; a base comprising a surface facing the bearing stud, the bearing stud and the surface forming a ball joint; and a plurality of tendons connected to the main body so as to control movement of the tool in two degrees of freedom.

Patent Agency Ranking